AcelRx Pharmaceuticals, Inc. (ACRX) Earns “Buy” Rating from Roth Capital

Roth Capital restated their buy rating on shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in a report published on Thursday morning. The firm currently has a $12.50 target price on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Zacks Investment Research downgraded AcelRx Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, July 11th. Jefferies Group LLC reissued a buy rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Friday, July 14th. ValuEngine raised AcelRx Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, July 24th. Stifel Nicolaus raised AcelRx Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday. Finally, HC Wainwright reissued a buy rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. AcelRx Pharmaceuticals has a consensus rating of Hold and a consensus target price of $7.50.

AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 2.95 on Thursday. The stock has a 50 day moving average of $2.77 and a 200-day moving average of $2.78. The company’s market capitalization is $133.87 million. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. Equities analysts expect that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “AcelRx Pharmaceuticals, Inc. (ACRX) Earns “Buy” Rating from Roth Capital” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://transcriptdaily.com/2017/08/13/acelrx-pharmaceuticals-inc-acrx-earns-buy-rating-from-roth-capital.html.

In other AcelRx Pharmaceuticals news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $2.40, for a total value of $2,100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 28.10% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ACRX. Virtu KCG Holdings LLC increased its position in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares in the last quarter. LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals during the second quarter valued at $319,000. WealthTrust Axiom LLC increased its position in AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares in the last quarter. Bank of New York Mellon Corp increased its position in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares in the last quarter. Finally, ING Groep NV increased its position in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares in the last quarter. 30.39% of the stock is owned by institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply